ArticleAllergy2026
MAIT Cells Suppress IgE-Mediated Asthma via IFNγ-Dependent B Cell Regulation.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMucosal-associated invariant T (MAIT) cells are innate-like lymphocytes enriched in mucosal tissues, but their role in allergic asthma pathogenesis remains poorly defined. In this study, we sought to elucidate the role of MAIT cells in a T cell-dominant model of allergic asthma.
methodsWe used a murine model of house dust mite-induced asthma and a selective MAIT cell antagonist (Acetyl-6-formylpterin, A6FP) to inhibit MAIT cell activation in vivo. Airway hyperresponsiveness, lung inflammation, serum IgE, and cytokine profiles were assessed. In vitro co-culture experiments evaluated the direct impact of MAIT cells on B cell IgE production.
resultsPharmacologic inhibition of MAIT cells exacerbated airway hyperresponsiveness and elevated circulating IgE without altering airway eosinophilia or T helper type 2/type 17 cytokine production. MAIT cell antagonism failed to increase AHR in IgE-deficient mice. In vitro, activated MAIT cells directly suppressed B cell IgE production through IFNγ signaling. IL-4 was sufficient to enhance IFNγ production by MAIT cells, suggesting that allergic inflammation may induce a counter-regulatory response from MAIT cells to limit IgE-mediated pathology.
conclusionMAIT cells limit airway hyperresponsiveness by suppressing IgE production through IFNγ-dependent B cell regulation. These findings define a previously unrecognized immunoregulatory function of MAIT cells in allergic asthma and suggest that enhancing MAIT cell activity may represent a therapeutic strategy for IgE-mediated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.